Tags

Type your tag names separated by a space and hit enter

Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
Curr HIV/AIDS Rep. 2013 Jun; 10(2):142-51.CH

Abstract

Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered--including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of "next-generation" PrEP agents to improve on this effective technology.

Authors+Show Affiliations

Department of Global Health, University of Washington, Seattle, WA 98104, USA. jbaeten@uw.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

23494772

Citation

Baeten, Jared M., and Robert Grant. "Use of Antiretrovirals for HIV Prevention: what Do We Know and what Don't We Know?" Current HIV/AIDS Reports, vol. 10, no. 2, 2013, pp. 142-51.
Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep. 2013;10(2):142-51.
Baeten, J. M., & Grant, R. (2013). Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Current HIV/AIDS Reports, 10(2), 142-51. https://doi.org/10.1007/s11904-013-0157-9
Baeten JM, Grant R. Use of Antiretrovirals for HIV Prevention: what Do We Know and what Don't We Know. Curr HIV/AIDS Rep. 2013;10(2):142-51. PubMed PMID: 23494772.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of antiretrovirals for HIV prevention: what do we know and what don't we know? AU - Baeten,Jared M, AU - Grant,Robert, PY - 2013/3/16/entrez PY - 2013/3/16/pubmed PY - 2013/12/16/medline SP - 142 EP - 51 JF - Current HIV/AIDS reports JO - Curr HIV/AIDS Rep VL - 10 IS - 2 N2 - Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered--including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of "next-generation" PrEP agents to improve on this effective technology. SN - 1548-3576 UR - https://www.unboundmedicine.com/medline/citation/23494772/Use_of_antiretrovirals_for_HIV_prevention:_what_do_we_know_and_what_don't_we_know L2 - https://dx.doi.org/10.1007/s11904-013-0157-9 DB - PRIME DP - Unbound Medicine ER -